主页 > 医学讨论 >
【medical-news】阻止心源性猝死的突破性进展
Breakthrough In Preventing Sudden Cardiac Death
The physicians at Westside Medical Associates of Los Angeles (WMALA) in conjunction with Westside Medical Imaging have implemented the use of the novel and exciting Micro-T-Wave Alternans technology for identifying patients at risk for sudden cardiac death (SCD). In the United States over 500,000 people die from SCD with no warning symptoms whatsoever; often times in the prime of life. People at risk for SCD include those who have suffered from a myocardial infarction (heart attack), cardiomyopthy (weakened heart muscle), a history of ventricular arrhythmias, syncope (fainting) and prolonged QT-interval.
Micro-T-Wave Alternans, manufactured by Cambridge Heart, is a non-invasive assessment of the electrical signals from the heart with mild exercise using sophisticated engineering algorithms. Patients who have abnormal examinations are at heightened risk of SCD and may benefit from defibrillator placement. Patients who have a negative result may not need to undergo defibrillator placement. The results of this examination need to be incorporated into other information your physician may have so that the appropriate treatment decisions are made for you.
Cambridge Heart (http://www.cambridgeheart.com) is engaged in the development and commercialization of products for the non-invasive diagnosis of cardiac disease, particularly the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary Microvolt T-Wave Alternans measurement technologies, coupled with its patented Spectral Analytic Method and ultra-sensitive disposable electrodes. The Micro-T-Wave Alternans test is included in the Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death jointly developed by the American College of Cardiology (ACC), The American Heart Association (AHA) and the European Society of Cardiology (ESC).
WMALA has the most sophisticated outpatient cardiac diagnostic centers in the United States. If you have any questions regarding Micro-T-Wave Alternans, or you feel that you may be at risk for sudden cardiac death, please contact Norman Lepor MD or Hooman Madyoon MD at Westside Medical Associates of Los Angeles located in Beverly Hills at (310) 289-9955. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Breakthrough In Preventing Sudden Cardiac Death
预防心源性猝死的新突破
The physicians at Westside Medical Associates of Los Angeles (WMALA) in
conjunction with Westside Medical Imaging have implemented the use of the
novel and exciting Micro-T-Wave Alternans technology for identifying
patients at risk for sudden cardiac death (SCD). In the United States
over 500,000 people die from SCD with no warning symptoms whatsoever;
often times in the prime of life. People at risk for SCD include those
who have suffered from a myocardial infarction (heart attack), cardiomyopthy
(weakened heart muscle), a history of ventricular arrhythmias, syncope (fainting)
and prolonged QT-interval.
洛山机西部医学会的医生联合西部医学影像协会已经实现应用新颖而令人兴奋的T微波交替技术来鉴定病人发生心源性猝死(SCD)的风险性。在美国超过50万人在毫无预兆的情况下死于SCD，且多在生命的最佳时段。有SCD危险的病人包括那些患有心肌梗死（心脏病发作），心肌炎（心肌受损），室性心率失常发作史，晕厥（昏厥）及长Q-T间期综合征的人。
Micro-T-Wave Alternans, manufactured by Cambridge Heart, is a
non-invasive assessment of the electrical signals from the heart
with mild exercise using sophisticated engineering algorithms.
Patients who have abnormal examinations are at heightened risk of
SCD and may benefit from defibrillator placement. Patients who
have a negative result may not need to undergo defibrillator
placement. The results of this examination need to be incorporated
into other information your physician may have so that the
appropriate treatment decisions are made for you.
T微波交替由剑桥心脏研制，是一种运用精确工程学计算轻度运动后的心肌电信号的无创检测方法。如果病人的检测结果为阴性则可能无需安置电除颤仪。这种检查结果需要结合你的医生掌握的治疗资料来制定适合你的治疗方案。
Cambridge Heart (http://www.cambridgeheart.com) is engaged in the development and commercialization of products for the non-invasive
diagnosis of cardiac disease, particularly the identification of
those at risk of sudden cardiac arrest. The Company's products
incorporate its proprietary Microvolt T-Wave Alternans measurement
technologies, coupled with its patented Spectral Analytic Method
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-09 17:22
医学,生命科学网